A Long-Term Safety Study of OZURDEX® in Clinical Practice

Allergan

Status: Completed

Conditions: Macular Edema; Uveitis, Posterior; Retinal Vein Occlusion

Treatments: Drug: dexamethasone 700 μg intravitreal implant

Study type: Observational

Funder types: Industry

Identifiers

NCT01539577

206207-025

Details and patient eligibility

About

This study is a multicenter, prospective, observational study to evaluate the long-term safety of OZURDEX® in patients with macular oedema following central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) or patients with non-infectious posterior segment uveitis in real-world clinical practice.

Enrollment: 875 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Macular oedema following either BRVO or CRVO or non-infectious uveitis
• Requires treatment with OZURDEX®

Exclusion criteria

• Current participation in any clinical study

Trial design

875 participants in 1 patient group

OZURDEX®

Description:

OZURDEX® (dexamethasone 700 μg intravitreal implant) administered according to general clinical practice.

Treatment:

Drug: dexamethasone 700 μg intravitreal implant